Sort   by:  
 Page size 
UnknownCDX2 as a Prognostic Biomarker in Colon Cancer.
Not available
S-EPMC7521111 | biostudies-literature
UnknownTAS-102, a novel antitumor agent: a review of the mechanism of action.
Not available
S-EPMC4624296 | biostudies-literature
UnknownSafety and Tolerability of c-MET Inhibitors in Cancer.
Not available
S-EPMC7491978 | biostudies-literature
UnknownCaveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.
Not available
S-EPMC3633716 | biostudies-literature
UnknownThe role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Not available
S-EPMC7493706 | biostudies-literature
UnknownBody Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Not available
S-EPMC5070548 | biostudies-literature
UnknownPrecision medicine in cholangiocarcinoma.
Not available
S-EPMC6087799 | biostudies-literature
UnknownPractical considerations in the use of regorafenib in metastatic colorectal cancer.
Not available
S-EPMC7607787 | biostudies-literature
UnknownSurrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Not available
S-EPMC5512363 | biostudies-literature
UnknownThe PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
Not available
S-EPMC5784655 | biostudies-literature
Sort   by:  
 Page size